Drug intelligence / Profile preview

Entrozyme

Development stage: Unknown
Lead developer: Stadmed
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Entrozyme is a digestive enzyme combination product developed and marketed by Stadmed Private Limited. It contains two primary active ingredients: pepsin (10 mg) and fungal diastase (50 mg). Pepsin is a proteolytic enzyme that facilitates the breakdown of dietary proteins into smaller peptides, while fungal diastase (a form of alpha-amylase) aids in the digestion of starch and complex carbohydrates by hydrolyzing them into simpler sugars. The medication is indicated for the treatment of digestive disturbances, dyspepsia, and conditions characterized by impaired production of gastric juices. It is formulated as oral tablets and is currently available in the Indian pharmaceutical market.

Brand names: Entrozyme

Beyond the preview

Go deeper on Entrozyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entrozyme.

Explore the full profile